These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17172580)

  • 21. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?
    Dressler D; Zettl U; Benecke R; Bigalke H
    Mov Disord; 2000 Nov; 15(6):1279-81. PubMed ID: 11104225
    [No Abstract]   [Full Text] [Related]  

  • 23. Is Botulinum Toxin Type A Efficacious, Safe, and Tolerable in Cervical Dystonia?: A Cochrane Review Summary With Commentary.
    Oral A
    Am J Phys Med Rehabil; 2020 Jul; 99(7):649-651. PubMed ID: 32251106
    [No Abstract]   [Full Text] [Related]  

  • 24. The increasing popularity of Botox injections.
    Zaidi Z
    J Pak Med Assoc; 2007 Feb; 57(2):53-5. PubMed ID: 17370783
    [No Abstract]   [Full Text] [Related]  

  • 25. Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia.
    Burguera JA; Villaroya T; López-Alemany M
    Clin Neuropharmacol; 2000; 23(4):226-8. PubMed ID: 11020130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cervical dystonia: from pathophysiology to pharmacotherapy.
    Patel S; Martino D
    Behav Neurol; 2013; 26(4):275-82. PubMed ID: 22713419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Do not say more Botox!].
    Junod V
    Rev Med Suisse; 2012 Feb; 8(326):288-9. PubMed ID: 22364079
    [No Abstract]   [Full Text] [Related]  

  • 28. [Botulinum toxin treatment in children].
    Sätilä H; Vähäsarja V; Paavilainen P
    Duodecim; 2011; 127(22):2417-24. PubMed ID: 22238919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?
    Duarte GS; Rodrigues FB; Ferreira JJ; Costa J
    Parkinsonism Relat Disord; 2018 Nov; 56():16-19. PubMed ID: 29910156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin treatment of axial and cervical dystonia.
    Benecke R; Dressler D
    Disabil Rehabil; 2007 Dec; 29(23):1769-77. PubMed ID: 18033602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complications with the use of botulinum toxin.
    Klein AW
    Dermatol Clin; 2004 Apr; 22(2):197-205, vii. PubMed ID: 15222580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain Metabolic Changes of Cervical Dystonia with Spinocerebellar Ataxia Type 1 after Botulinum Toxin Therapy.
    Kikuchi A; Takeda A; Sugeno N; Miura E; Kato K; Hasegawa T; Baba T; Konno M; Oshima R; Watanuki S; Hiraoka K; Tashiro M; Aoki M
    Intern Med; 2016; 55(14):1919-22. PubMed ID: 27432104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased Pulmonary Function During Botulinum Toxin A Therapy for Chronic Migraines in a 17-Year-Old Female.
    Oliver JD; Boesch RP; Mack KJ
    Headache; 2018 Sep; 58(8):1259-1261. PubMed ID: 30033516
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report.
    Santamato A; Ranieri M; Panza F; Frisardi V; Micello MF; Filoni S; Fiore P
    J Rehabil Med; 2012 Sep; 44(9):795-7. PubMed ID: 22915045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder.
    Chapple C
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S1. PubMed ID: 25042136
    [No Abstract]   [Full Text] [Related]  

  • 37. Bilateral Lower Sternocleidomastoid Botulinum Toxin Injections to Address Refractory Anterocollis.
    Peng-Chen Z; Thompson A; Rodriguez RL
    Neurologist; 2016 Mar; 21(2):30-1. PubMed ID: 26926853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
    Walter U; Mühlenhoff C; Benecke R; Dressler D; Mix E; Alt J; Wittstock M; Dudesek A; Storch A; Kamm C
    Neurology; 2020 May; 94(20):e2109-e2120. PubMed ID: 32332130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications.
    Dressler D; Wohlfahrt K; Meyer-Rogge E; Wiest L; Bigalke H
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2182-7. PubMed ID: 21134050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of botulinum toxin type A on vibration induced facilitation of motor evoked potentials in spasmodic torticollis.
    Urban PP; Rolke R
    J Neurol Neurosurg Psychiatry; 2004 Nov; 75(11):1541-6. PubMed ID: 15489383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.